"Fibrinolytic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
| Descriptor ID |
D005343
|
| MeSH Number(s) |
D27.505.519.421.750 D27.505.954.411.320 D27.505.954.502.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolytic Agents".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolytic Agents".
This graph shows the total number of publications written about "Fibrinolytic Agents" by people in this website by year, and whether "Fibrinolytic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 3 | 6 |
| 2000 | 1 | 2 | 3 |
| 2001 | 6 | 2 | 8 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 2 | 3 | 5 |
| 2005 | 2 | 2 | 4 |
| 2006 | 5 | 2 | 7 |
| 2007 | 5 | 2 | 7 |
| 2008 | 6 | 0 | 6 |
| 2009 | 4 | 4 | 8 |
| 2010 | 2 | 2 | 4 |
| 2011 | 9 | 2 | 11 |
| 2013 | 8 | 2 | 10 |
| 2014 | 3 | 2 | 5 |
| 2015 | 4 | 2 | 6 |
| 2016 | 4 | 1 | 5 |
| 2017 | 3 | 3 | 6 |
| 2018 | 4 | 3 | 7 |
| 2019 | 5 | 3 | 8 |
| 2020 | 3 | 4 | 7 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 10 | 10 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 0 | 3 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fibrinolytic Agents" by people in Profiles.
-
Comparison of combined intravenous and intra-arterial thrombolysis with intravenous thrombolysis alone in stroke patients undergoing mechanical thrombectomy: a propensity-matched analysis. J Neurointerv Surg. 2025 Jun 01; 17(e2):e261-e268.
-
Intrapleural tissue plasminogen activator and deoxyribonuclease in complex pleural effusion and empyema, clinical outcomes, and predictors. Ther Adv Respir Dis. 2025 Jan-Dec; 19:17534666251343711.
-
Anti-stroke biologics: from recombinant proteins to stem cells and organoids. Stroke Vasc Neurol. 2024 Nov 05; 9(5):467-480.
-
Meta-Analysis Comparing Oral Anticoagulant Monotherapy Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease. Clin Cardiol. 2024 Oct; 47(10):e70026.
-
Histotripsy and Catheter-Directed Lytic: Efficacy in Highly Retracted Porcine Clots In Vitro. Ultrasound Med Biol. 2024 08; 50(8):1167-1177.
-
Outcomes of Pleural Space Infections in Patients With Indwelling Pleural Catheters for Active Malignancies. J Bronchology Interv Pulmonol. 2024 Apr 01; 31(2):155-159.
-
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024 07; 106(1):145-153.
-
Comparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry. Stroke. 2024 Mar; 55(3):532-540.
-
Apixaban for Prevention of Thromboembolism in Pediatric Heart?Disease. J Am Coll Cardiol. 2023 12 12; 82(24):2296-2309.
-
Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. Ann Neurol. 2024 Feb; 95(2):347-361.